
-
Syria says deadly Israeli strikes a 'blatant violation'
-
Financial markets tumble after Trump tariff announcement
-
Starbucks faces new hot spill lawsuits weeks after $50mn ruling
-
Europe riled, but plans cool-headed response to Trump's tariffs
-
'Shenmue' voted most influential video game ever in UK poll
-
New coal capacity hit 20-year low in 2024: report
-
Revealed: Why monkeys are better at yodelling than humans
-
Key details on Trump's market-shaking tariffs
-
'A little tough love': Top quotes from Trump tariff talk
-
US business groups voice dismay at Trump's new tariffs
-
Grealish dedicates Man City goal to late brother
-
US tariffs take aim everywhere, including uninhabited islands
-
Trump sparks trade war with sweeping global tariffs
-
Israeli strikes hit Damascus, central Syria; monitor says 4 dead
-
Slot 'hates' offside rule that gave Liverpool win over Everton
-
US stocks end up, but volatility ahead after latest Trump tariffs
-
Barca oust Atletico to set up Clasico Copa del Rey final
-
Mourinho grabs Galatasaray coach's face after losing Istanbul derby
-
Grealish strikes early as Man City move up to fourth in Premier League
-
Reims edge out fourth-tier Cannes to set up PSG French Cup final
-
Liverpool beat Everton as title looms, Man City win without Haaland
-
Jota wins bad-tempered derby as Liverpool move 12 points clear
-
Inter and Milan level in derby Italian Cup semi
-
Stuttgart beat Leipzig to reach German Cup final
-
Trump unveils sweeping global tariffs
-
Italian director Nanni Moretti in hospital after heart attack: media
-
LIV Golf stars playing at Doral with Masters on their minds
-
Trump unveils sweeping 'Liberation Day' tariffs
-
Most deadly 2024 hurricane names retired from use: UN agency
-
Boeing chief reports progress to Senate panel after 'serious missteps'
-
Is Musk's political career descending to Earth?
-
On Mexico-US border, Trump's 'Liberation Day' brings fears for future
-
Starbucks faces new hot spill lawsuit weeks after $50mn ruling
-
Ally of Pope Francis elected France's top bishop
-
'Determined' Buttler leads Gujarat to IPL win over Bengaluru
-
US judge dismisses corruption case against New York mayor
-
Left-wing party pulls ahead in Greenland municipal elections
-
Blistering Buttler leads Gujarat to IPL win over Bengaluru
-
Tesla sales slump as pressure piles on Musk
-
Amazon makes last-minute bid for TikTok: report
-
Canada Conservative leader warns Trump could break future trade deal
-
British band Muse cancels planned Istanbul gig
-
'I'll be back' vows Haaland after injury blow
-
Trump to unveil 'Liberation Day' tariffs as world braces
-
New coach Edwards adamant England can win women's cricket World Cup
-
Military confrontation 'almost inevitable' if Iran nuclear talks fail: French FM
-
US stocks advance ahead of looming Trump tariffs
-
Scramble for food aid in Myanmar city near quake epicentre
-
American Neilson Powless fools Visma to win Across Flanders
-
NATO chief says alliance with US 'there to stay'

Breast cancer drug shown to reduce recurrence risk
Even when the disease is caught early, breast cancer recurrence is relatively commonplace -- and for survivors, the prospect can be daunting.
A drug developed by Swiss pharmaceutical maker Novartis reduced this risk by a quarter in a large group of early-stage survivors of the most common type of breast cancer, according to clinical trial results presented Friday at the American Society of Clinical Oncology's (ASCO) annual meeting, offering patients new hope.
The study of ribociclib, which belongs to a newer class of drugs known as molecularly targeted therapies, was described as a "very important and practice-changing clinical trial," by ASCO expert Rita Nanda, who was not involved in the research.
The majority of the two million new breast cancers diagnosed globally are in the early phases of disease, defined as stages I through III.
"The current standard of therapy for these patients is surgery followed by chemotherapy... or radiation, then followed by between five and 10 years of hormonal blockade by various endocrine therapies," lead author Dennis Slamon of the UCLA Jonsson Comprehensive Cancer Center told reporters.
But recurrence is as high as more than one in three people for stage I, and more than one in two in stage III, with the cancer sometimes returning decades later.
The clinical trial involved more than 5,100 people with stage II and stage III forms of HR-positive, HER2-negative breast cancer, which is the most common subtype, making up nearly 70 percent of all breast cancer cases in the United States.
Half the patients received ribociclib -- marketed under the brand name Kisqali -- as well as hormonal therapy, while the other half received only hormonal therapy. They continued for a treatment period of three years.
But the trial was halted early because a significant difference in outcomes between the two groups became apparent, and it would not have been ethical to allow the hormone therapy-only group to miss out on the more effective treatment.
Overall, 7.4 percent of patients in the ribociclib group experienced a recurrence against 9.2 percent of patients in the hormone therapy-only group, which means an approximate risk reduction of 25 percent.
"Ribociclib also showed more favorable outcomes in overall survival, recurrence-free survival, and distant disease-free survival," a press statement said.
While ribociclib, which is already widely approved around the world, has previously shown benefit for people with metastatic breast cancer, the new study was able to demonstrate it also improves outcomes for people with earlier stages, including those with cancer that hasn't yet spread to the lymph nodes.
The most common side effects were abnormally low counts of a type of white blood cell called neutrophils, as well as joint pain. Less common effects included gastrointestinal issues and fatigue.
Ribociclib works by disrupting proteins in breast cancer cells responsible for cell division.
Novartis plans to continue to study longer-term outcomes.
F.Dubois--AMWN